Securities Class Action Allegations Cast Shadow Over Regeneron Pharmaceuticals (REGN)– Hagens Berman

Core Viewpoint - Regeneron Pharmaceuticals, Inc. is facing a securities fraud class action following a significant drop in its stock price, which resulted in a loss of approximately $9 billion in market value due to alleged misleading statements regarding its EYLEA® product [1][5]. Group 1: Legal Issues and Investigations - Hagens Berman has initiated an investigation into Regeneron for potentially misleading investors about its marketing and reimbursement practices related to EYLEA®, urging affected investors to report their losses [2][6]. - The class action lawsuit focuses on Regeneron's compliance with regulations concerning Medicare reimbursement claims, particularly regarding EYLEA® [3]. - The complaint alleges that Regeneron made false statements and failed to disclose various practices that misrepresented the pricing and sales of EYLEA®, including undisclosed credit card fees that effectively lowered the selling price [4]. Group 2: Financial Impact - On October 31, 2024, Regeneron reported disappointing Q3 2024 financial results, with U.S. net sales for EYLEA® and EYLEA HD® increasing only 3% year-over-year, attributed to lower net selling prices and pricing pressure in the anti-VEGF category [5]. - The announcement of these financial results led to a more than 9% decline in Regeneron's share price on the same day [5].